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ABSTRACT

This invention relates to a ribonucleic acid (RNA) based
assay system for body fluid identification, and in particular to
a novel, multiplex, parallel assay system based on messenger
RNA expressed in human tissue, and to a method for using the
same.
6 Claims, 2 Drawing Sheets
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Real-time PCR Primer and Probe Sequences.
Primer and Probe Sequences/dyes
F: 5'- ATG GAA ATC CCA TCA CCA TCT T (Seq ID 1)
R: 5'- CGC CCC ACT TGA TIT TGG (Seq ID 2)
P: 5'-NED-CAG GAG CGA GAT CC (Seq ID 3)
GNAS
F: 5'-TGA ACG CCG CAA GTG GAT (Seq JD 4)
R: 5'-GGC GGTTGG TCTGGTTGT C (Seq ID 5)
P: 5'-NED- CTI CAA CGA TGT GAC TGC (Seq JD 6)
ALAS2
F: 5' - GCC GAC ACC CTC AGG TCT T (Seq ID 7)
Blood
R: 5'- GAA ACT TAC TGG TGC CTG AGA TGT T (Seq ID 8)
P: 5'-VIC- AAG CCA CAC AGG AGA C (Seq ID 9)
SPTB
F: 5'-GCC TIT AAT GCC CTG ATA CAC AA (Seq ID 10)
R: 5'- GAG TCC TIC AGC TIA TCA AAG TCG AT (Seq ID 11)
P: 5'- FAM- CAC CGG CCC GAC CT (Seq ID 12)
HTN3
F: 5'- CTI GGC TCT CAT GCT TIC CAT (Seq ID 13)
Saliva
R: 5'-TIT ATA CCC ATG ATG TCTCTITGCA(Seq ID 14)
P: 5'-FAM-ACT GGA GCT GAT TCA C (Seq ID 15)
STATH
F: 5'-TCT TGG CTC TCA TGG TIT CCA (Seq ID 16)
R: 5'- CCA ATT CTA CGC AAA AAT TIC TCT T (Seq ID 17)
P: 5'-VIC- ATT GGA GCT GAT TCA TC (Seq ID 18)
PRMl
F: 5'- CAG ATA TIA CCG CCA GAG ACA AAG (Seq ID 19)
Semen
R: 5'-AAT TAG TGT CTI CTA CAT CTC GGT CTG T (Seq JD 20)
P: 5'-FAM-CAG CAC CTC ATG GCT (Seq ID 21)
PRM2
F: 5'- GGC GCA AAA GAC GCT CC (Seq ID 22)
R: 5'- GCC CAG GAA GCT TAG TGC C (Seq ID 23)
P: 5'-VIC-TIC TGC AGC CTC TGC GAT (Seq ID 24)
Menstrual
F: 5'- GGG AGG CAT GAG TGA GCT ACA (Seq ID 25)
MMP-7
Blood
R: 5'- TGG CAT TIT TIG TIT CTG AGT CAT A (Seq ID 26)
P: 5'-FAM-AAC AGG ere AGG ACT AT (Seq ID 27)
MMP-10 F: 5'-TGG TCA CTI CAG CTC CTI TCC T (Seq ID 28)
R: 5'- AAT GGC AGA ATC AAC AGC ATC TC (Seq ID 29)
P: 5 '-VIC- CAC CTT ACA TAC AGG A TT G (Seq ID 30)
F=forward primer, R=reverse primer, P=probe
Body Fluid
Housekeeping
Gene

Gene
GAPDH

Figure 1
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Real-time PCR nrimer and nrobe for bod11 fluid identification trinlexes
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MESSENGER RNA PROFILING: BODY
FLUID IDENTIFICATION USING
MULTIPLEX REAL TIME-POLYMERASE
CHAIN REACTION (Q-PCR)

secretions, and urine identification can be problematic. The
need exists for a more reliable, efficient assay system to
supplant conventional methods for body fluid identification.
Previous research in the development of a ribonucleic acid
(RNA) based assay system for the identification of body
fluids, included considerations for the use of protein and
messenger RNA (mRNA) since both are expressed in a tissuetype specific manner. However, multiplex analysis of complex protein mixtures, such as those present in body fluid
stains, requires further developments in the field of proteomics. Whereas, messenger RNA (mRNA), the molecular intermediate between genetic deoxyribonucleic acid (DNA) and
expressed protein, is, at present, supported by technologies
for massively parallel analysis in the field of genomics.
As reported by B. Alberts, et al. Molecular Biology of the
Cell 3rd ed., Garland Publishing Inc., NY, 1994, a pattern of
gene expression is produced that is unique to each cell type
and is evinced by the presence, as well as, the relative abundance of specific mRNAs. Each cell type, such as, blood
monocytes, lymphocytes, ejaculated spermatozoa, epithelial
cells lining the oral cavity or epidermal cells, has a unique
pattern of gene expression.
Specific gene expression patterns for saliva were reported
by J. Juusola and J. Ballantyne in February 2002 in a presentation to the American Academy of Forensic Science (AAFS)
entitled, "The Development of an RNA Based Assay System
for Body Fluid Identification," and in Forensic Science International, Vol. 135 (2003) pages 85-96 ("Messenger RNA
Profiling: a Prototype Method to Supplant Conventional
Methods for Body Fluid Identification"). Semen specific
genes were reported by J. Juusola and J. Ballantyne in "The
Development of an RNA Based Assay System for Body Fluid
Identification," presented toAAFS, February 2002. M. Bauer
and D. Patzelt also identified semen specific genes in an
article, "Protamine mRNA as Molecular Marker for Spermatozoa in Semen Stains," International Journal ofLegal Medicine Vol. 117 (2003) pages 17 5-179. Additionally, M. Bauer
and D. Patzelt identified menstrual blood specific genes in an
article, "Evaluation of mRNA markers for the identification
of menstrual blood," Jl. Forensic Science Vol. 47 (6) November (2002) pages 1278-1282.
As more and more tissue-specific genes (mRNAs) are identified for use in the positive identification of body fluids and
tissues of forensic importance, there is an increasing need for
a device or assay system that provides simultaneous and
semi-automated analysis through a common assay format.
The novel, multiplex, parallel assay system of the present
invention provides a common assay format and offers many
advantages over the conventional analysis procedures for
body fluid identification.

This invention claims the benefit of priority from U.S.
Provisional Application Ser. No. 60/612,057 filed Sep. 22,
2004 the content of which is incorporated herein by reference.
FIELD OF THE INVENTION
This invention relates to a ribonucleic acid (RNA) based
assay system for body fluid identification, and in particular to
a novel, multiplex, parallel assay system based on messenger
RNA expressed in human tissue, and to a method for using the
same.

10

15

SEQUENCE LISTING
Appendix A is a sequence listing of DNA sequences identified in FIG. 1; the content of Appendix A is also submitted
on a compact disc and is incorporated herein by reference.
Attached hereto is one compact disc containing the following
files:
SEQ. 1 Housekeeping gene GAPDH (Seq. ID 1)
SEQ. 2 Housekeeping gene GAPDH (Seq. ID 2)
SEQ. 3 Housekeeping gene GAPDH (Seq. ID 3)
SEQ. 4 Housekeeping gene GNAS (Seq. ID 4)
SEQ. 5 Housekeeping gene GNAS (Seq. ID 5)
SEQ. 6 Housekeeping gene GNAS (Seq. ID 6)
SEQ. 7 BloodALAS2 (Seq. ID 7)
SEQ. 8 BloodALAS2 (Seq. ID 8)
SEQ. 9 BloodALAS2 (Seq. ID 9)
SEQ. 10 Blood SPTB (Seq. ID 10)
SEQ. 11 Blood SPTB (Seq. ID 11)
SEQ. 12 Blood SPTB (Seq. ID 12)
SEQ. 13 Saliva HTN3 (Seq. ID 13)
SEQ. 14 Saliva HTN3 (Seq. ID 14)
SEQ. 15 Saliva HTN3 (Seq. ID 15)
SEQ. 16 Saliva STATH (Seq. ID 16)
SEQ. 17 Saliva STATH (Seq. ID 17)
SEQ. 18 Saliva STATH (Seq. ID 18)
SEQ. 19 Semen PRMl (Seq. ID 19)
SEQ. 20 Semen PRMl (Seq. ID 20)
SEQ. 21 Semen PRMl (Seq. ID 21)
SEQ. 22 Semen PRM2 (Seq. ID 22)
SEQ. 23 Semen PRM2 (Seq. ID 23)
SEQ. 24 Semen PRM2 (Seq. ID 24)
SEQ. 25 Menstrual Blood MMP-7 (Seq. ID 25)
SEQ. 26 Menstrual Blood MMP-7 (Seq. ID 26)
SEQ. 27 Menstrual Blood MMP-7 (Seq. ID 27)
SEQ. 28 Menstrual Blood MMP-10 (Seq. ID 28)
SEQ. 29 Menstrual Blood MMP-10 (Seq. ID 29)
SEQ. 30 Menstrual Blood MMP-10 (Seq. ID 30)
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SUMMARY OF THE INVENTION
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BACKGROUND AND PRIOR ART
Conventional methods of body fluid identification use a
variety oflabor-intensive, technologically diverse techniques
that are performed in a series, not parallel, manner and are
costly in terms of time and consumption of sample. It used to
be standard practice to perform biochemical, serological, and
immunological tests to identify the body fluid(s) comprising
a biological stain. Increasingly, however, classical methods
for body fluid identification have no confirmatory technique
for some frequently encountered body fluids. For example,
there is no definitive test for the presence of saliva or vaginal
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A primary objective of the present invention is to provide
facile identification of the tissue components present in a
body fluid stain.
A second objective of the present invention is to supplant
the battery of serological and biochemical tests currently
employed in the forensic serology laboratory.
A third objective of the present invention is to provide a
common assay format that -provides greater specificity in the
identification of body fluids with improved timeliness.
A fourth objective of the present invention is to decrease
sample consumption during analysis of stains containing
body fluids.

US 7,588,921 Bl
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A fifth objective of the present invention is to provide
simultaneous and semi-automated analysis through a common assay format.
A sixth objective of the present invention is to provide a
multiplex analysis of body fluids in an assay format that is
compatible with DNA analysis methodologies.
A preferred method for identifying the presence or absence
of at least four body fluids from a human being in a single or
mixed stain, includes obtaining a sample stain consisting of a
body fluid from a human being, extracting total ribonucleic
acid (RNA) from the sample stain, treating the total RNA with
an enzyme, initiating a reverse-transcriptase (RT) reaction by
treating total RNA with random decamers to produce cDNA,
amplifying the cDNA using body fluid specific genes (BFG)specific unlabeled primers and the corresponding labeled
probe, identifying the body fluid by determining the values of
a house keeping gene (HSK) and the value of the BFG, and
then subtracting the value of the BFG from the value of the
HSK gene, wherein a positive value for both BFGs would
indicate the presence of the BFG in the bodily fluid. The more
preferred method for identifying the presence or absence ofat
least four body fluids from a human being in a single or mixed
stain, further includes extracting the total RNA with a denaturing solution. The preferred extracting solution is guanidine
isothiocyanate-phenol:chloroform and the extracted total
RNA is precipitated with an organic solvent, which is preferably isopropanol.
The preferred enzyme used to treat the extracted total RNA
is deoxyribonuclease I (DNase I).
It is preferred that the method of the present invention
include four body fluids selected from the group consisting of
one or more of blood, saliva, semen and menstrual blood,
wherein portions of two BFG's identifying one particular
body fluid and one HSK gene are present, providing a triplex
assay.
It is more preferred that the probes fluoresce and the values
are determined by finding the cycle threshold (Ct) of the HSK
and each of the BFG and then subtracting the Ct of the BFG
from the Ct of the HSK and the HSK is selected from at least
one ofGAPDH or GNAS.
Preferably, the BFG is one or more of the group consisting
ofALAS2, SPTB, STATH, HTN3, PRMl, PRM2, MMP-7,
andMMP-10.
A preferred kit for use in identifying the presence or
absence of a bodily fluid, comprising BFG and HSK specific
primers and probes is provided. More preferably the BFG
specific primers are constructed from one or more of the
group consisting of the ALAS2, SPTB, STATH, HTN3,
PRMl, PRM2, MMP-7, and MMP-10 genes. The preferred
housekeeping gene is selected from at least one of GAPDH
and GNAS.
Preferably, the primers for the preferred kit, are one or
more sequences selected from the group consisting of 5'-atggaa-atc-cca-tca-cca-tct-t (Seq ID 1), 5'-cgc-ccc-act-tga-tt-tgg
(Seq ID 2), 5'-tga-acg-ccg-caa-gtg-gat (Seq ID 4), 5'-ggc-ggttgg-tct-ggt-tgt-c (Seq ID 5), 5'-gcc-gac-acc-ctc-agg-tct-t (Seq
ID 7), 5'-gaa-act-tac-tgg-tgc-ctg-aga-tgt-t (Seq ID 8), 5'-gccttt-aat-gcc-ctg-ata-cac-aa (Seq ID 10), 5'-gag-tcc-ttc-agc-ttatca-aag-tcg-at (Seq ID 11 ), 5'-ctt-ggc-tct-cat-gct-ttc-cat (Seq
ID 13), 5'-m-ata-ccc-atg-atg-tct-ctt-tgc-a (Seq ID 14), 5'-tcttgg-ctc-tca-tgg-ttt-cca (Seq ID 16), 5'-cca-att-cta-cgc-aaaaat-ttc-tct-t (Seq ID 17), 5'-cag-ata-tta-ccg-cca-gag-aca-aag
(Seq ID 19), 5'-aat-tag-tgt-ctt-cta-cat-ctc-ggt-ctg-t (Seq ID
20), 5'-ggc-gca-aaa-gac-gct-cc (Seq ID 22), 5'-gcc-cag-gaagct-tag-tgc-c (Seq ID 23), 5'-ggg-agg-cat-gag-tga-gct-aca
(Seq ID 25), 5'-tgg-cat-ttt-ttg-ttt-ctg-agt-cat-a (Seq ID 26),

5'-tgg-tca-ctt-cag-ctc-ctt-tcc-t (Seq ID 0.28), 5'-aat-ggc-agaatc-aac-agc-atc-tc (Seq ID 29).
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The preferred primers for identifying the source of body
fluids comprising one or more of the group consisting of
(ALAS2 primers) 5'-gcc-gac-acc-ctc-agg-tct-t (Seq ID 7),
5'-gaa-act-tac-tgg-tgc-ctg-aga-tgt-t (Seq ID 8), (SPTB primers) 5'-gcc-ttt-aat-gcc-ctg-ata-cac-aa (Seq ID 10), 5'-gag-tccttc-agc-tta-tca-aag-tcg-at (Seq ID 11 ), (HTN3 primers) 5'-cttggc-tct-cat-gct-ttc-cat (Seq ID 13), 5'-ttt-ata-ccc-atg-atg-tctctt-tgc-a (Seq ID 14), (STATH primers) 5'-tct-tgg-ctc-tca-tggttt-cca (Seq ID 16), 5'-cca-att-cta-cgc-aaa-aat-ttc-tct-t (Seq
ID 17), (PRMl primers) 5'-cag-ata-tta-ccg-cca-gag-aca-aag
(Seq ID 19), 5'-aat-tag-tgt-ctt-cta-cat-ctc-ggt-ctg-t (Seq ID
20), (PRM2 primers) 5'-ggc-gca-aaa-gac-gct-cc (Seq ID 22),
5'-gcc-cag-gaa-gct-tag-tgc-c (Seq ID 23), (MMP-7 primers)
5'-ggg-agg-cat-gag-tga-gct-aca (Seq ID 25), 5'-tgg-cat-mttg-ttt-ctg-agt-cat-a (Seq ID 26), (MMP-10 primers) 5'-tggtca-ctt-cag-ctc-ctt-tcc-t (Seq ID 28), 5'-aat-ggc-aga-atc-aacagc-atc-tc (Seq ID 29).
The preferred primers for said housekeeping gene comprising one or more of the group consisting of (GAPDH
primers) 5'-atg-gaa-atc-cca-tca-cca-tct-t (Seq ID 1), 5'-cgcccc-act-tga-tt-tgg (Seq ID 2), (GNAS primers) 5'-tga-acgccg-caa-gtg-gat (Seq ID 4), 5'-ggc-ggt-tgg-tct-ggt-tgt-c (Seq
ID 5).
The preferred pro bes for the kit of the present invention, are
labeled with fluorescent dyes and the probes are one or more
sequences selected from the group consisting of 5'-cag-gagcga-gat-cc (Seq ID 3), 5'-ctt-caa-cga-tgt-gac-tgc (Seq ID 6),
5'-aag-cca-cac-agg-aga-c (Seq ID 9), 5'-cac-cgg-ccc-gac-ct
(Seq ID 12), 5'-act-gga-gct-gat-tca-c (Seq ID 15), 5'-att-ggagct-gat-tca-tc (Seq ID 18), 5'-cag-cac-ctc-atg-gct (Seq ID 21 ),
5'-ttc-tgc-agc-ctc-tgc-gat (Seq ID 24), 5'-aac-agg-ctc-aggact-at (Seq ID 27), 5'-cac-ctt-aca-tac-agg-att-g (Seq ID 30).
The preferred probes for identifying the source of body
fluids comprising one or more of the group consisting of
(ALAS2 probe) 5'-aag-cca-cac-agg-aga-c (Seq ID 9), (SPTB
probe) 5'-cac-cgg-ccc-gac-ct (Seq ID 12), (HTN3 probe)
5'-act-gga-gct-gat-tca-c (Seq ID 15), (STATH probe) 5'-attgga-gct-gat-tca-tc (Seq ID 18), (PRMl probe) 5'-cag-cac-ctcatg-gct (Seq ID 21), (PRM2 probe) 5'-ttc-tgc-agc-ctc-tgc-gat
(Seq ID 24),(MMP-7 probe) 5'-aac-agg-ctc-agg-act-at (Seq
ID 27), (MMP-10 probe) 5'-cac-ctt-aca-tac-agg-att-g (Seq ID
30); more preferably the kit uses probes wherein ALAS2
probe 5'-aag-cca-cac-agg-aga-c (Seq ID 9) is labeled with
VIC, SPTB probe 5'-cac-cgg-ccc-gac-ct (Seq ID 12) is
labeled with FAM, HTN3 probe 5'-act-gga-gct-gat-tca-c (Seq
ID 15) is labeled with FAM, STATH probe 5'-att-gga-gct-gattca-tc (Seq ID 18) is labeled with VIC, PRMl probe 5'-cagcac-ctc-atg-gct (Seq ID 21) is labeled with FAM, PRM2
probe 5'-ttc-tgc-agc-ctc-tgc-gat (Seq ID 24) is labeled with
VIC, MMP-7 probe 5'-aac-agg-ctc-agg-act-at (Seq ID 27) is
labeled with FAM, MMP-10 probe 5'-cac-ctt-aca-tac-aggatt-g (Seq ID 30) is labeled with VIC.
The preferred probes for said housekeeping genes comprising one or more of the group consisting of (GAPDH
probe) 5'-cag-gag-cga-gat-cc (Seq ID 3), (GNAS probe)
5'-ctt-caa-cga-tgt-gac-tgc (Seq ID 6); more preferably the
invention uses probes, wherein GAPDH probe 5'-cag-gagcga-gat-cc (Seq ID 3) is labeled with NED, GNAS probe
5'-ctt-caa-cga-tgt-gac-tgc (Seq ID 6) is labeled with NED.
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Further objectives and advantages of this invention will be
apparent from the following detailed description and example
of a presently preferred embodiment.

Gene-specific unlabeled forward and reverse primers
along with fluorescent dye-labeled probes for any two genes
identified above and a housekeeping gene, are incorporated
into a single, triplexed real-time polymerase chain reaction
(qPCR). During amplification, the fluorescent dye from the
gene-specific probe is released and produces a fluorescent
signal that is detected by the real-time PCR instrument. The
resulting fluorescence signals identify the body fluids that are
present in the sample as a single or mixed stain. For this
invention, the body fluids include, but are not limited to,
blood, saliva, semen or menstrual blood
The following example provides further explanation of the
present invention.

BRIEF DESCRIPTION OF THE DRAWING
FIG. 1 shows the DNA sequences of the PCR primers for
the various body fluid-specific genes and housekeeping genes
used in the assay.
FIG. 2 shows the optimum DNA primer and probe concentrations for each gene in each triplex.
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DESCRIPTION OF THE PREFERRED
EMBODIMENTS
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Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the
invention is not limited in its application to the details of the
particular arrangements shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
The invention provides a multiplex, parallel assay to identify the tissue source for at least four body fluids from a
human being. The first step in the development of the invention has been the identification of tissue-specific genes that
are expressed in only one tissue. For example, each tissue type
is comprised of cells that have a unique transcriptome, or gene
expression profile, also known as the messenger ribonucleic
acid (mRNA) profile. The collection of genes that are
expressed within the constellation of differentiated cells that
make up a body fluid is called the multicellulartranscriptome.
These genes comprise ubiquitously expressed housekeeping
(HSK) genes such as GAPDH and GNAS, which are responsible for cell maintenance functions, and genes that are specifically expressed in certain tissues only. The mRNA mo!ecules are present in different quantities depending on the
particular species of mRNA and the cell type, and can be
classified as abundant, moderately abundant and rare.
Although the present invention is dependent on the identification of tissue-specific mRNA molecules, it is not to be
considered a limitation of the invention. As previously discussed, tissue-specific genes are still in the process of being
identified.
The present invention provides a body fluid identification
system containing real time PCR triplexes that are able to
recognize each of the candidate genes.
An example of some of the body fluid-specific genes for
each of four body fluids that are the subject of the present
invention, are identified in the table below:
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BODYFLUIDSPECIFIC GENE:
Delta-arninolevulinate
synthase 2 (erythoid)
(ALAS2)
Beta-spectrin (SPTB)
Statherin (STATH)
Histatin 3 (HTN3)
Protamine 1 (PRMl)
Protamine 2 (PRM2)
Matrix
metalloproteinase 7
(MMP-7)
Matrix
metalloproteinase 10
(MMP-10)

BODY FLUIDS
BLOOD

55

BLOOD
SALIVA
SALIVA
SEMEN
SEMEN

60
MENSTRUAL
BLOOD
MENSTRUAL
BLOOD
65

EXAMPLE
A physiological stain is prepared by collecting human
blood via venipuncture; collecting 50 microliter (µ!) aliquots
placed onto cotton gauze and dried at room temperature.
Freshly ejaculated semen is collected in plastic cups, and
allowed to dry onto cotton swabs at room temperature. Buccal
scrapings and saliva samples were obtained on cotton swabs,
and dried at room temperature. Vaginal secretions, such as
menstrual blood, are also obtained and dried at room temperature. For RNA or DNA isolation a 50 microliter (µ!)
bloodstain or a single semen, menstrual blood or saliva
stained cotton swab is used.
For RNA isolation, total RNA is extracted from blood,
saliva, vaginal secretions and semen stains with a denaturing
solution, such as, guanidine isothiocyanate-phenol:chloroform and precipitated with isopropanol. Next, the extracted
total RNA is treated with an enzyme, deoxyribonuclease I
(DNase I), and then reverse-transcribed using random decamers as the first strand primer, producing complementary DNA
(cDNA). Finally, the cDNA is amplified using gene-specific
primers.
Based on the above extraction and separation techniques, a
multiplex reverse-transcription polymerase chain reaction
(RT-PCR) assay is developed for the definitive identification
of all of the body fluids commonly encountered in forensic
casework analysis, namely blood, saliva, semen, and menstrual blood. The triplexes are composed of two body fluidspecific genes and a housekeeping (HSK) gene, GAPDH
(glyceraldehyde-3-phospate dehydrogenase) or GNAS (guanine nucleotide binding protein, alpha stimulating) or others,
and have been optimized for the detection of blood, saliva,
semen, and menstrual blood as single or mixed stains. The
methodology is based on gene expression profiling analysis
in which the body fluid-specific genes are identified by
detecting the presence of appropriate mRNA species. Genespecific unlabeled primers and the corresponding probe
labeled with a fluorescent dye, such as VIC, FAM or NED, are
incorporated into a single multiplexed real-time polymerase
chain reaction (qPCR). VIC, FAM and NED are commercially available, trademarked fluorescent dyes.
The primers and probes are custom synthesized commercially according to our specifications. Invitrogen Corporation
(Carlsbad, Calif.) synthesized the primers and the labeled
probes are fromAppliedBiosystems (Foster City, Calif.). The
unique primer and probe sequences are shown in FIG. 1. For
the body fluid identification triplexes, optimal primer and
probe concentrations were determined experimentally and
are as follows: For the blood triplex (SPTB/ALAS2/
GAPDH), the primer concentrations were 900/900/300 nM,
respectively, and the probe concentrations were 2501250175
nM, respectively. For the blood triplex (SPTB/ALAS2/
GNAS), the primer concentrations were 900 nM for each
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primer and the probe concentrations were 250 nM for each
probe. For the saliva triplex (HTN3/STATH/GAPDH), the
primer concentrations were 90019001600 nM, respectively,
and the probe concentrations were 250/250/150 nM, respectively. For the saliva triplex (HTN3/STATH/GNAS), the
primer concentrations were 900 nM for each primer, and the
probe concentrations were 20012501250 nM for each probe.
In the semen triplex (PRM1/PRM2/GAPDH), the optimal
primer concentration was 900 nM for each gene, and the
probe concentration was 250 nM for each gene. For the semen
triplex (PRM1/PRM2/GNAS), the optimal primer concentrations were 900/900/1200 nM, and the probe concentrations
were 250/250/300 nM, respectively. For the menstrual blood
triplex (MMP-7 /MMP-11/GAPDH), the primer concentrations were 900/900/150 nM, respectively, and the probe concentrations were 2501250175 nM, respectively. For the menstrual blood triplex (MMP-7 /MMP-11/GNAS), the primer
concentrations were 900/900/300 nM, respectively, and the
probe concentrations were 200/250/150 nM, respectively.
These optimal primer and probe concentrations are also listed
in FIG. 2, however, these concentrations should not limit the
invention as other concentrations will also be functional.
As the polymerase chain reaction (PCR) product is amplified, the gene-specific probe is cleaved and the fluorescent
dye is released producing a fluorescence signal that is
detected by the real-time PCR instrument. The resulting fluorescence signals identify the body fluids that are present in the
sample as a single or mixed stain. The resulting fluorescence
signal and corresponding Ct value can be used to identify
those body fluids present by determining the delta Ct (dCt)

values generated using the cycle threshold (Ct) of the housekeeping gene (HSK) and the Ct of each of the body fluid
specific genes (BFG), (Ct HSK-Ct BFG). Ct is the cycle
number at which the fluorescent signal passes a pre-determined threshold. Depending on the body fluid-specific genes
(BF Gs) being tested, two positive dCt values would indicate
the presence of a particular body fluid, while two negative dCt
values would indicate the absence of that body fluid.
Whereas, one positive dCt and one negative dCt would indicate the possible presence of that body fluid and suggest the
need for additional testing of the sample. However, this
approach is not limited to utilizing fluorescence as a detection
method, as other detection methods may be used. Also, data
analysis is not limited to utilizing the calculations described
above, as other methods of calculation may be used.
Advantages of the mRNA-based approach, compared to
conventional biochemical analysis include, but are not limited to, greater specificity, simultaneous and semi-automated
analysis through a common assay format, improved timeliness, decreased sample consumption and compatibility with
DNA extraction methodologies.
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope of
the invention is not intended to be, nor should it be deemed to
be, limited thereby and such other modifications or embodiments as may be suggested by the teachings herein are particularly reserved especially as they fall within the breadth
and scope of the claims here appended.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 30
<210>
<211>
<212>
<213>
<220>
<221>
<222>
<223>

SEQ ID NO 1
LENGTH, 16
TYPE, DNA
ORGANISM, homo sapiens
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1) .. (1)
OTHER INFORMATION, n is a, c, g,

t

or u

<400> SEQUENCE, 1
ndcaggagcg agatcc

<210>
<211>
<212>
<213>

16

SEQ ID NO 2
LENGTH, 22
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 2
atggaaatcc catcaccatc t t

<210>
<211>
<212>
<213>

22

SEQ ID NO 3
LENGTH, 18
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 3
cgccccactt gattttgg

<210> SEQ ID NO 4

18
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-continued

<211> LENGTH, 18
<212> TYPE, DNA
<213> ORGANISM, homo sapiens
<400> SEQUENCE, 4
tgaacgccgc aagtggat

<210>
<211>
<212>
<213>

18

SEQ ID NO 5
LENGTH, 19
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 5
ggcggttggt ctggttgtc

<210>
<211>
<212>
<213>
<220>
<221>
<222>
<223>

SEQ ID NO 6
LENGTH, 20
TYPE, DNA
ORGANISM, homo sapiens
FEATURE,
NAME/KEY, misc feature
LOCATION, (1) .. (1)
OTHER INFORMATION, n is a, c, g,

19

t

or u

<400> SEQUENCE,
ndcttcaacg atgtgactgc

<210>
<211>
<212>
<213>

20

SEQ ID NO 7
LENGTH, 19
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 7
gccgacaccc tcaggtctt

<210>
<211>
<212>
<213>

19

SEQ ID NO 8
LENGTH, 25
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 8
gaaacttact ggtgcctgag atgtt

<210>
<211>
<212>
<213>

25

SEQ ID NO 9
LENGTH, 18
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 9
vcaagccaca caggagac

<210>
<211>
<212>
<213>

18

SEQ ID NO 10
LENGTH, 23
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 10
gcctttaatg ccctgataca caa

<210>
<211>
<212>
<213>

SEQ ID NO 11
LENGTH, 26
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 11

23
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gagtccttca gcttatcaaa gtcgat

<210>
<211>
<212>
<213>

26

SEQ ID NO 12
LENGTH, 14
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 12
caccggcccg acct

<210>
<211>
<212>
<213>

14

SEQ ID NO 13
LENGTH, 21
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 13
cttggctctc atgctttcca t

<210>
<211>
<212>
<213>

21

SEQ ID NO 14
LENGTH, 25
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 14
tttataccca tgatgtctct ttgca

<210>
<211>
<212>
<213>

25

SEQ ID NO 15
LENGTH, 16
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 15
actggagctg attcac

<210>
<211>
<212>
<213>

16

SEQ ID NO 16
LENGTH, 21
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 16
tcttggctct catggtttcc a

<210>
<211>
<212>
<213>

21

SEQ ID NO 17
LENGTH, 25
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 17
ccaattctac gcaaaaattt ctctt

<210>
<211>
<212>
<213>

25

SEQ ID NO 18
LENGTH, 17
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 18
attggagctg attcatc

<210>
<211>
<212>
<213>

SEQ ID NO 19
LENGTH, 24
TYPE, DNA
ORGANISM, homo sapiens

17
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-continued
<400> SEQUENCE, 19
cagatattac cgccagagac aaag

<210>
<211>
<212>
<213>

24

SEQ ID NO 20
LENGTH, 28
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 20
aattagtgtc ttctacattc tggtctgt

<210>
<211>
<212>
<213>

28

SEQ ID NO 21
LENGTH, 15
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 21
cagcacctca tggct

<210>
<211>
<212>
<213>

15

SEQ ID NO 22
LENGTH, 17
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 22
ggcgcaaaag acgctcc

<210>
<211>
<212>
<213>

17

SEQ ID NO 23
LENGTH, 19
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 23
gcccaggaag cttagtgcc

<210>
<211>
<212>
<213>

19

SEQ ID NO 24
LENGTH, 20
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 24
vcttctgcag cctctgcgat

<210>
<211>
<212>
<213>

20

SEQ ID NO 25
LENGTH, 21
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 25
gggaggcatg agtgagctac a

<210>
<211>
<212>
<213>

21

SEQ ID NO 26
LENGTH, 25
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 26
tggcattttt tgtttctgag tea ta

<210>
<211>
<212>
<213>

SEQ ID NO 27
LENGTH, 17
TYPE, DNA
ORGANISM, homo sapiens

25
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16
-continued

<400> SEQUENCE, 27
17

aacaggctca ggactat

<210>
<211>
<212>
<213>

SEQ ID NO 28
LENGTH, 22
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 28
tggtcacttc agctcctttc ct

<210>
<211>
<212>
<213>

22

SEQ ID NO 29
LENGTH, 23
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 29
23

aatggcagaa tcaacagcat etc

<210>
<211>
<212>
<213>

SEQ ID NO 30
LENGTH, 21
TYPE, DNA
ORGANISM, homo sapiens

<400> SEQUENCE, 30
vccaccttac atacaggatt g

We claim:
1. A method for identifying the presence of one or more
body fluids from a human being in a single or mixed stain the
fluids selected from the group consisting of non-menstrual
blood, menstrual blood, saliva and semen, comprising the
steps of:
a) obtaining a sample stain comprising a body fluid from a
human being;
b) extracting total ribonucleic acid (RNA) from the sample
stain;
c) treating the total RNA from step b) with an enzyme
d) initiating a reverse-transcriptase (RT) reaction by treating the total RNA from step c) with random decamers to
produce cDNA;
e) amplifying a pair of body-fluid specific genes (BF Gs)
selected from the pairs: ALAS2 and SPTB, specific for
non-menstrual blood, HTN3 and STATH, specific for
saliva, PRMl and PRM2, specific for semen, and
MMP-7 and MMP-10, specific for menstrual blood,
wherein said amplifying utilizes two primers and a
probe for each BFG;
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f) amplifying a housekeeping gene (HSK) selected from
one of GAPDH and GNAS, wherein said amplifying
utilizes two primers and a probe for each HSK;
g) determining the presence of the body fluid in the stain by
measuring the cycle threshold (Ct) value-of the house
keeping gene (HSK) and the Ct values ofboth BFGs, and
then subtracting the Ct value of each BFG from the Ct
value of the HSK gene, wherein a positive dCt (HSK-Ct
minus BFG-Ct) value of each BFG indicates the presence of the corresponding body fluid in the stain.
2. The method of claim 1, wherein the total RNA is
extracted with a denaturing solution.
3. The method of claim 2, wherein the extracting solution is
guanidine isothiocyanate-phenol:chloroform.
4. The method of claim 3, wherein the extracted total RNA
is precipitated with an organic solvent.
5. The method of claim 4, wherein the organic solvent is
isopropanol.
6. The method of claim 1, wherein the enzyme used to treat
the extracted total RNA is deoxyribonuclease I (DNase I).
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